Bayer's Pipeline Advances and Europe's Farm Gap Share One Question: Where's the Revenue?

Bayer has handed investors a cluster of announcements that look like momentum but measure very differently. A trial has begun, a regulatory filing has been accepted, a consultancy has documented Europe's lagging farm productivity, and JPMorgan has restated its confidence in the stock. None of these is a sales figure. That distinction sits at the heart of how the shares should be read ahead of the company's third-quarter 2026 results, scheduled for 3 November 2026.

The most recent item came Thursday, when Bayer's subsidiary Vividion Therapeutics treated the first patient in a global Phase II combination study. The trial pairs VVD-214 with pembrolizumab in previously untreated patients with advanced MSI-high or dMMR colorectal cancer — a deliberately narrow population, not colorectal disease at large. "Previously untreated" refers to first-line therapy in advanced illness, not to early-stage disease. Dosing a first patient opens a clinical program; it says nothing yet about whether the combination works, let alone what it might earn.

A Filing Is Not an Approval

Roughly two weeks earlier, the FDA accepted Bayer's application to extend Finerenon's label to chronic kidney disease in patients without diabetes, based on positive Phase III FIND-CKD data. Acceptance moves the file into review. It is not the grant of the extension itself, and treating the two as equivalent would book a step that has not yet been taken. The FIND-CKD results bolster the medical case; any revenue from the broader label remains prospective.

Laid side by side, the two developments occupy different stages of the same long road. One is a study under way, the other a regulatory application in hand. Lumping them together as a new approval or a secured growth spurt overstates both.

Europe's Fields Tell a Slower Story

Bayer's own commissioned research, conducted by Oxford Economics, points to a structural constraint on the agricultural side of the business. Arable production in the EU grew just 0.1% a year between 2011 and 2023, against 2% globally. The company uses that gap to press for faster access to farming innovations and a more suitable regulatory framework.

The study frames a problem and supports a policy argument. What it does not show is that conditions have already shifted. A large innovation gap can represent an opportunity, but it substitutes for neither market access nor demonstrated commercial benefit — a distinction that matters for anyone weighing the stock conservatively.

What JPMorgan Sees

JPMorgan on Friday reiterated an "Overweight" rating with a price target of 61 euros. That is a valuation view, not evidence of future earnings. In the bull case, further operating proof would underpin such confidence; the analyst note itself does not supply it.

The pessimistic scenario does not require every project to fail. It is enough that progress keeps accumulating on the procedural and research level without visible commercial effect. What would justify a re-rating is Bayer drawing a more convincing line between innovation and business performance.

The November Test

Until the quarterly report, investors face a two-track picture: advances in drug development on one side, group financials on the other. The bull case holds as long as Bayer can tie further development steps to a more persuasive economic outlook. Should the impression harden that milestones remain confined to filings and first-patient visits, a more cautious reading would be understandable.

The pending judgment, then, is not a choice between boundless optimism and outright rejection. It concerns the evidentiary bar: how much commercial confirmation investors need before they assign greater value to the pipeline's progress.